interestingly they are having a decent run - mostly off the back of MSB momentum: There is definitely a trading strategy for someone who wants exposure to the prospects of the stem cell industry (MSB approval will float all boats) but doesn't want the full brunt of a potential CRL impact (upside will also not be as great as it will be for MSB, but will benefit nonetheless from MSBs success in that scenario).
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-724
-
- There are more pages in this discussion • 373 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.005(0.45%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.12 | $1.08 | $1.558M | 1.431M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 76058 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 27976 | 4 |
View Market Depth
| Last trade - 12.30pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |